Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000921895-25-000843
Filing Date
2025-03-21
Accepted
2025-03-21 11:58:25
Documents
4

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 31060
2 TRANSACTIONS IN SECURITIES ex2to13da109076068_032125.htm EX-2 21423
3 GROUP AGREEMENT, DATED MARCH 20, 2025 ex991to13da109076068_032125.htm EX-99.1 30856
4 POWERS OF ATTORNEY ex992to13da109076068_032125.htm EX-99.2 13984
  Complete submission text file 0000921895-25-000843.txt   98803
Mailing Address 2727 KIRBY DRIVE UNIT 29L HOUSTON TX 77098
Business Address
Radoff Bradley Louis (Filed by) CIK: 0001380585 (see all company filings)

Type: SCHEDULE 13D/A

Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Subject) CIK: 0001593899 (see all company filings)

EIN.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91836 | Film No.: 25759653
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)